Author response to "A step closer to optimal paroxetine dosing: what is next?".
作者信息
Liao Yundan, Yue Weihua
机构信息
Peking University Sixth Hospital, Peking University Institute of Mental Health, NHC Key Laboratory of Mental Health (Peking University), National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), Beijing, China.
Peking University Sixth Hospital, Peking University Institute of Mental Health, NHC Key Laboratory of Mental Health (Peking University), National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), Beijing, China.
出版信息
EBioMedicine. 2025 Apr;114:105651. doi: 10.1016/j.ebiom.2025.105651. Epub 2025 Mar 19.
Abstract
摘要
相似文献
1
Author response to "A step closer to optimal paroxetine dosing: what is next?".
EBioMedicine. 2025 Apr;114:105651. doi: 10.1016/j.ebiom.2025.105651. Epub 2025 Mar 19.
2
A step closer to optimal paroxetine dosing: what is next?
EBioMedicine. 2025 May;115:105650. doi: 10.1016/j.ebiom.2025.105650. Epub 2025 Apr 24.
3
Optimal dose regimen for paroxetine.
J Clin Psychiatry. 1992 Feb;53 Suppl:21-6.
4
Paroxetine: a selective serotonin reuptake inhibiting antidepressant.
Ann Pharmacother. 1993 Oct;27(10):1212-22. doi: 10.1177/106002809302701012.
5
Effects of repeated selective serotonin reuptake inhibitor paroxetine treatments on mouse forced swimming.
Methods Find Exp Clin Pharmacol. 1999 Nov;21(9):599-601.
6
Luteal phase dosing with paroxetine controlled release (CR) in the treatment of premenstrual dysphoric disorder.
Am J Obstet Gynecol. 2005 Aug;193(2):352-60. doi: 10.1016/j.ajog.2005.01.021.
7
Optimizing the individual dosing of paroxetine in major depressive disorder with therapeutic drug monitoring.
J Psychopharmacol. 2024 Dec;38(12):1063-1070. doi: 10.1177/02698811241278779. Epub 2024 Sep 25.
8
Multiple dose pharmacokinetics of paroxetine in children and adolescents with major depressive disorder or obsessive-compulsive disorder.
Neuropsychopharmacology. 2006 Jun;31(6):1274-85. doi: 10.1038/sj.npp.1300960.
9
Precision dosing-based optimisation of paroxetine during pregnancy for poor and ultrarapid CYP2D6 metabolisers: a virtual clinical trial pharmacokinetics study.
J Pharm Pharmacol. 2020 Aug;72(8):1049-1060. doi: 10.1111/jphp.13281. Epub 2020 Apr 28.
10
Pharmacokinetics of paroxetine, a selective serotonin reuptake inhibitor, in Grey parrots (Psittacus erithacus erithacus): influence of pharmaceutical formulation and length of dosing.
J Vet Pharmacol Ther. 2013 Feb;36(1):51-8. doi: 10.1111/j.1365-2885.2012.01391.x. Epub 2012 Mar 21.
本文引用的文献
1
Dose adjustment of paroxetine based on CYP2D6 activity score inferred metabolizer status in Chinese Han patients with depressive or anxiety disorders: a prospective study and cross-ethnic meta-analysis.
EBioMedicine. 2024 Jun;104:105165. doi: 10.1016/j.ebiom.2024.105165. Epub 2024 May 21.
2
Model-Informed Precision Dosing: Background, Requirements, Validation, Implementation, and Forward Trajectory of Individualizing Drug Therapy.
Annu Rev Pharmacol Toxicol. 2021 Jan 6;61:225-245. doi: 10.1146/annurev-pharmtox-033020-113257. Epub 2020 Oct 9.
3
An economic model of the cost-utility of pre-emptive genetic testing to support pharmacotherapy in patients with major depression in primary care.
Pharmacogenomics J. 2019 Oct;19(5):480-489. doi: 10.1038/s41397-019-0070-8. Epub 2019 Jan 16.
4
Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017.
Pharmacopsychiatry. 2018 Jan;51(1-02):9-62. doi: 10.1055/s-0043-116492. Epub 2017 Sep 14.
5
Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response.
Mol Psychiatry. 2004 May;9(5):442-73. doi: 10.1038/sj.mp.4001494.
Zotero 插件